Registry for Polycystic Liver Disease in the UK

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Polycystic Liver Disease (PLD) registry in the UK is an observational study that aims to understand the natural progression of polycystic liver disease. It is part of a larger international registry led by Radboud University Medical Center in the Netherlands. The study collects both prospective and retrospective data, including responses from a validated questionnaire specific to PLD. This registry will help gather insights on patient characteristics, risk factors, symptoms, quality of life, and treatment strategies within the largest cohort of PLD patients to date.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with PLD with more than 10 liver cysts
* Patients with PKD and PLD with more than 10 liver cysts

Exclusion Criteria:

* Patients with PKD or PLD with less than 10 liver cysts

Where it's running

• Radboud University Medical Center
  Nijmegen, Netherlands Recruiting
• Portmouth Hospitals University NHS Trust
  Portsmouth, Hampshire, United Kingdom Recruiting

Study contacts

• Study coordinator: Richard Aspinall, BSc, MBChB, PhD
• Email: richard.aspinall@porthosp.nhs.uk
• Phone: 02392286255

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using a GnRH Agonist to Treat Severe Polycystic Liver Disease in Women

  This study is testing if a medication called leuprorelin can help reduce liver size in women with severe polycystic liver disease who are still experiencing growth despite other treatments.

  Recruiting Phase 2 University Medical Center Groningen · Nijmegen, Gelderland and 1 other locations · NCT05478083

• Observing the effects of foam sclerotherapy on kidney and liver cysts

  This study is testing if foam sclerotherapy can help reduce the size of large kidney and liver cysts in people with polycystic kidney and liver diseases and improve their quality of life over a year.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT04111692

• Managing Depressive Symptoms in ADPKD: testing Digital Neurotherapy and Capacity Coaching

  This study tests whether Digital Neurotherapy or Capacity Coaching can help people with ADPKD who have depression and self-reported pain, compared to education alone.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07745920

• AZD1613 safety and how the body handles it in adults with ADPKD

  We will test whether AZD1613 given under the skin or into a vein is safe and how the body processes it in adults with ADPKD who have eGFR between 45 and 90 mL/min/1.73m2.

  Recruiting at 10 sites Phase 1 AstraZeneca · Birmingham, Alabama and 14 other locations · NCT07228364

• Intravenous ABBV-CLS-628 for adults with autosomal dominant polycystic kidney disease

  This trial will test whether intravenous ABBV-CLS-628 given every 4 weeks is safe and helps adults with ADPKD.

  Recruiting at 72 sites Phase 2 Calico Life Sciences LLC · Birmingham, Alabama and 90 other locations · NCT06902558

• National Registry for Rare Kidney Diseases

  This study is collecting health information from people with rare kidney diseases to help improve treatments and create better care guidelines.

  Recruiting UK Kidney Association · Bristol, South West · NCT06065852

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.